Equibles does not estimate personal net worth.
Get an email with a short summary when Tonix Pharmaceuticals Holding Corp. publishes a filing, an earnings call transcript or a press release.
Get TNXP alertsSeth Lederman is recorded as Board Member at Tonix Pharmaceuticals Holding Corp. (TNXP) since May 7, 2026 and CEO at Tonix Pharmaceuticals Holding Corp. (TNXP). The newest filing on record that lists Seth Lederman as CEO at Tonix Pharmaceuticals Holding Corp. (TNXP) is dated March 30, 2026. Tonix Pharmaceuticals Holding Corp. reported in an 8-K filed May 7, 2026 that Seth Lederman was appointed Director, effective May 7, 2026. The proxy statement of Tonix Pharmaceuticals Holding Corp. reports total compensation of $3,168,830 for Seth Lederman in fiscal 2025, including a base salary of $702,000. Disclosed compensation is on record for 8 fiscal years. Seth Lederman has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Tonix Pharmaceuticals Holding Corp. on August 11, 2026. Tonix Pharmaceuticals Holding Corp. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tonix Pharmaceuticals Holding Corp. includes Bradley Saenger (CFO), Siobhan Fogarty (CTO), Adeoye Olukotun (Board Member) and 7 others.
“The Company's shareholders elected nine individuals to the Board of Directors as set forth below:”
“Well, first of all, thank you all for coming. Thank you very much for having me and Tonics at the conference. And it has been an exciting couple of days, an exciting 15 years.”
“We're pleased to welcome you to Tonics' earnings call. Today, we're reporting second quarter financial results and operational highlights that reflect strong execution in both our commercial business and advancing our development pipeline.”
2026-05-07–present
Start not stated–present
Last confirmed March 30, 2026
Biotechnology · Healthcare
CEO, Board Member
2026-05-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $702,000 | $3,168,830 |
| 2024 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $675,000 | $1,809,767 |
| 2023 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $675,000 | $2,050,065 |
| 2022 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $675,000 | $4,580,167 |
| 2021 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $675,000 | $7,708,389 |
| 2020 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $614,250 | $3,874,822 |
| 2019 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $585,000 | $1,288,273 |
| 2018 | Tonix Pharmaceuticals Holding Corp. (TNXP) | Chief Executive Officer | $472,500 | $1,477,445 |
